

PROGRAM	INDICATION	Preclinical	Phase 1	Phase 2	Phase 3	Market
GATTEX® (teduglutide)	Short Bowel Syndrome	█	█	█	█	█
NATPARA™ (recombinant human parathyroid hormone (rhPTH(1-84)))	Hypoparathyroidism	█	█	█	█	
Teduglutide	Crohn's Disease*	█	█	█		
NPSP790	Autosomal dominant hypocalcemia with hypocalciuria (ADHH)	█				
NPSP795	Autosomal dominant hypocalcemia with hypocalciuria (ADHH)	█				
Teduglutide	Pediatric Indications	█				
Teduglutide	GI Mucositis	█				

*This indication is outside our core focus and would only be pursued as a specialty indication or on a partnered basis.